About 5 results found for searched term "56-47-3" (0.059 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2619 | Deoxycorticosterone acetate | Animal Modeling |
| DOCA; 11-Deoxycorticosterone acetate; DOC acetate; Cortexone acetate | ||
| Deoxycorticosterone acetate, an adrenocorticotropic hormone and also a precursor of aldosterone, as well as a salicorticoid receptor (MR) agonist, can be used to construct rat models of hypertension. | ||
| M8109 | UK-371,804 HCl | Others |
| UK-371,804 is a reversible, substrate-competitive, highly potent (Ki = 10 nM) and selective urokinase-type plasminogen activator (uPA) Inhibitor with excellent selectivity over tPA, plasmin, Factor IXa and Xa. | ||
| M17428 | 4,9-Dihydroxy-α-lapachone | Quinones |
| 4,9-Dihydroxy-α-lapachone | ||
| M24827 | Talacotuzumab | IL Receptor/Related |
| JNJ 56022473; CSL 362 | ||
| Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. | ||
| M52167 | (S)-ethyl 2-amino-4-fluoro-4-methylpentanoate | Amino Acid Derivatives |
| (S)-ethyl 2-amino-4-fluoro-4-methylpentanoate is a leucine derivative. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
